Risk factors for the development of MBC include larger tumor size, positive lymph node status, stage T3/T4 disease (Barinoff et al., 2013), hormone receptor (HR)-negative status, and human epidermal growth factor receptor-2 (HER2) overexpression (Beslija et al., 2009). The gene discussed is ERBB2; the disease is neoplasm.